Expert consensus on the diagnosis and treatment of anticancer drug-induced interstitial lung disease.
10.3760/cma.j.cn112152-20220412-00244
- VernacularTitle:抗肿瘤药物相关间质性肺病诊治专家共识
- Collective Name:Anticancer Drug-induced Interstitial Lung Disease Management Group
- Publication Type:Journal Article
- Keywords:
Anticancer drug;
Diagnosis;
Drug-induced interstitial lung disease;
Malignant tumor;
Treatment
- MeSH:
Antineoplastic Agents/adverse effects*;
Consensus;
Humans;
Lung;
Lung Diseases, Interstitial/diagnosis*;
Quality of Life
- From:
Chinese Journal of Oncology
2022;44(7):693-702
- CountryChina
- Language:Chinese
-
Abstract:
Drug-induced interstitial lung disease (DILD) is the most common pulmonary adverse events caused by anti-cancer treatment. In recent years, with the development of clinical oncology, a large amount of novel anti-cancer drugs have been approved and widely used in clinical practice, and the incidence of anti-cancer drug related DILD is gradually increasing. DILD lacks specific clinical manifestations or diagnostic criteria. If not treated properly, it may leads to interruption or discontinuation of anti-cancer treatment, or even become life threat in severe cases. Therefore, the Anti-cancer Drug-induced Interstitial Lung Disease Management Group have reached a consensus on the diagnosis and management of anti-cancer DILD after several rounds of discussion. This consensus aims to improve clinicians' awareness of anti-cancer drug related-DILD and proposes an algorithm for the diagnosis and treatment of this disease, and to improve patients' prognosis and quality of life.
